Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 8/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20427403 | 0.88 | CDA (0.39) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL16381996 | 0.88 | CDA (0.39) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL19229350 | 0.88 | CDA (0.39) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL15187536 | 0.84 | ADORA2A (0.38) | CDA | |
| SCHEMBL14583693 | 0.84 | ADORA2A (0.38) | CDA | |
| SCHEMBL18875014 | 0.84 | ADORA2A (0.38) | CDA | |
| SCHEMBL18593480 | 0.82 | CDA (0.34) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL15702140 | 0.82 | CDA (0.34) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL18798692 | 0.81 | CDA (0.33) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL16125739 | 0.79 | CDA (0.31) | CDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277576-A1 | A METHOD FOR PREVENTING OR TREATING A CORNAVIRUS INFECTIOUS DISEASE | HENAN GENUINE BIOTECH CO., LTD. (CN) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277576-A1 | A METHOD FOR PREVENTING OR TREATING A CORNAVIRUS INFECTIOUS DISEASE | ACE, ACE2, SARS1 | CDA 1502/4885PDE4D 3478/4885PDE3A 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.